Related Experiment Video
Updated: Jan 1, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells
Shensi Shen1, Sara Faouzi2,3, Amandine Bastide4
1INSERM U981, Gustave Roussy Cancer Campus, Villejuif, France. SHENSI.SHEN@gustaveroussy.fr.
Abstract:
Cancer persister cells tolerate anticancer drugs and serve as the founders of acquired resistance and cancer relapse. Here we show that a subpopulation of BRAFV600 mutant melanoma cells that tolerates exposure to BRAF and MEK inhibitors undergoes a reversible remodelling of mRNA translation that evolves in parallel with drug sensitivity. Although this process is associated with a global reduction in protein synthesis, a subset of mRNAs undergoes an increased efficiency in translation. Inhibiting the eIF4A RNA helicase, a component of the eIF4F translation initiation complex, abrogates this selectively increased translation and is lethal to persister cells. Translation remodelling in persister cells coincides with an increased N6-methyladenosine modification in the 5'-untranslated region of some highly translated mRNAs. Combination of eIF4A inhibitor with BRAF and MEK inhibitors effectively inhibits the emergence of persister cells and may represent a new therapeutic strategy to prevent acquired drug resistance.
Insights
Cancer persister cells can survive drug treatment by altering protein synthesis. Targeting the eIF4A RNA helicase with inhibitors can eliminate these cells, offering a new strategy against drug resistance and relapse.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer persister cells survive anticancer drugs, leading to acquired resistance and relapse.
- BRAF-mutant melanoma cells exhibit drug tolerance to BRAF and MEK inhibitors.
Purpose of the Study:
- To investigate the mechanisms of drug tolerance in cancer persister cells.
- To identify therapeutic strategies to overcome drug resistance in melanoma.
Main Methods:
- Analysis of mRNA translation remodeling in drug-tolerant BRAF-mutant melanoma cells.
- Inhibition of the eIF4A RNA helicase and its effect on persister cells.
- Assessment of N6-methyladenosine modification in mRNA.
Main Results:
- Drug-tolerant persister cells undergo reversible mRNA translation remodeling with selective translation efficiency increase.
- Inhibiting eIF4A RNA helicase abrogates selective mRNA translation and is lethal to persister cells.
- Increased N6-methyladenosine modification is observed in highly translated mRNAs within persister cells.
Conclusions:
- Targeting eIF4A in combination with BRAF and MEK inhibitors can prevent persister cell emergence.
- This combination therapy may offer a novel strategy to prevent acquired drug resistance in melanoma.
Related Concept Videos
MicroRNAs
MicroRNAs
Regulation of Expression at Multiple Steps
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulated mRNA Transport
RNA Stability

